Stock 4886 ASKA PHARMACEUTICAL HOLDINGS CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights ASKA Pharmaceutical Holdings Co.,Ltd.

Equities

4886

JP3119660003

Market Closed - Japan Exchange
Other stock markets
 12:02:15 05/06/2024 pm IST 		5-day change 1st Jan Change
2,295 JPY -0.04% Intraday chart for ASKA Pharmaceutical Holdings Co.,Ltd. -1.21% +28.64%
2023 Ha Tay Pharmaceutical JSC announced that it has received VND 180.6 billion in funding from ASKA Pharmaceutical Holdings Co.,Ltd. CI
2023 ASKA Pharmaceutical Holdings Co.,Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023 CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ASKA Pharmaceutical Holdings Co.,Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023
CI
Tranche Update on ASKA Pharmaceutical Holdings Co.,Ltd.'s Equity Buyback Plan announced on July 12, 2021.
CI
ASKA Pharmaceutical Holdings Co.,Ltd.'s Equity Buyback announced on July 12, 2021, has closed with 300,000 shares, representing 1.06% for ¥316.48 million.
CI
Tranche Update on ASKA Pharmaceutical Holdings Co.,Ltd.'s Equity Buyback Plan announced on July 12, 2021.
CI
Tranche Update on ASKA Pharmaceutical Holdings Co.,Ltd.'s Equity Buyback Plan announced on July 12, 2021.
CI
ASKA Pharmaceutical Holdings Co.,Ltd. announces an Equity Buyback for 300,000 shares, representing 1.05% for ¥350 million.
CI
ASKA Pharmaceutical Holdings Co.,Ltd. authorizes a Buyback Plan.
CI
ASKA Pharmaceutical Holdings Co., Ltd. acquired 20.04% stake in Japan Glass Industry Co., Ltd.
CI
Ribomic Inc. and ASKA Pharmaceutical Co., Ltd. Announces Execution of A Multi-Year Joint Research and Development Agreement for Drug Discovery Research and Development
CI
ASKA Pharmaceutical Co., Ltd. acquired additional 20% stake in Ha Tay Pharmaceutical JSC.
CI
ASKA Pharmaceutical Co., Ltd. completed the acquisition of 24.9% stake in Ha Tay Pharmaceutical JSC.
CI
ASKA Pharmaceutical Co., Ltd. signed an agreement to acquire 24.9% stake in Ha Tay Pharmaceutical JSC.
CI
Torii and ASKA Enter into Co-Promotion Agreement Concerning Additional Indication of Iron Deficiency Anemia for Riona
CI
ASKA Pharmaceutical Co., Ltd. Announces Dividend for the Year Ended March 31, 2020, Payable on June 26, 2020; Provides Dividend Guidance for the Second Quarter and Year Ended March 31, 2021; Reports Consolidated Earnings Results for the Year Ended March 31, 2020; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2021
CI
ASKA Pharmaceutical Co., Ltd. and Kinopharma, Inc. Enter into Option Agreement for Treatment of Cervical Dysplasia
CI
ASKA Pharmaceutical Co., Ltd. Reports Consolidated Earnings Results for the First Quarter Ended June 2019; Provides Consolidated Earnings Guidance for the Year Ending March 2020
CI
ASKA Pharmaceutical Co., Ltd. and Takeda Pharmaceutical Company Limited Enter into Licensing Agreement for Relugolix in Women's Health Indications
CI
Omnicare Drugs India Pvt. Ltd. and Aska Pharmaceuticals Co. Ltd. Enter into an Agreement to Establish A Joint Venture
CI
ASKA Pharmaceutical and Neopharma Agree to Establish a Joint Venture in India
CI
ASKA Pharmaceutical Co., Ltd. Reports Consolidated Earnings Results for the Six Months Ended September 30, 2017; Provides Consolidated Earnings Guidance for the Ending March 31, 2018
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4886 Stock
  4. News ASKA Pharmaceutical Holdings Co.,Ltd.
  5. Highlights